DaVita Inc.’s Stock Price Soars to $143.67, Marking a Robust 3.70% Increase

DaVita Inc. (DVA)

143.67 USD +5.13 (+3.70%) Volume: 1.18M

DaVita Inc.’s stock price soars to $143.67, witnessing a substantial trading session increase of +3.70% and a remarkable year-to-date growth of +37.14%, driven by a robust trading volume of 1.18M, consolidating DVA’s strong market performance.

Latest developments on DaVita Inc.

Today, DaVita Inc. (NYSE:DVA) stock price movements were influenced by several key events. Quadrant Capital Group LLC sold 202 shares, while Jump Financial LLC lowered their position and also sold shares of DaVita Inc. Principal Securities Inc. took a position in the company, Vanguard Personalized Indexing Management LLC sold 236 shares, and Neuberger Berman Group LLC trimmed their stock holdings. Additionally, Coldstream Capital Management Inc. made a new $280,000 investment in DaVita Inc., all contributing to the fluctuations in the stock price today.

A look at DaVita Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

DaVita Inc. is expected to see strong growth and momentum in the long term, according to Smartkarma Smart Scores. With high scores in Growth and Momentum, the company is positioned well for future expansion and market performance. However, the lower scores in Value and Resilience may indicate some potential areas of concern that investors should keep an eye on.

Despite facing challenges in terms of value and resilience, DaVita Inc. remains a key player in the healthcare industry, providing essential kidney dialysis services to patients worldwide. The company’s strong growth and momentum scores suggest that it has the potential to continue thriving in the long term, making it a notable player to watch in the healthcare sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma